← Back to Search

FDG PET/CT for Lung Cancer

N/A
Waitlist Available
Led By Daniel Pryma, MD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult patients, at least 18 years of age
Patients with NSCLC diagnosis who have been referred for a clinical FDG PET/CT staging scan as part of their standard of care
Must not have
Children, fetuses, neonates, or prisoners
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trialstudied how imaging works to diagnose lung cancer in the chest, to improve accuracy.

Who is the study for?
This trial is for adults over 18 with a diagnosis of non-small cell lung cancer (NSCLC) who need an FDG PET/CT scan as part of their usual care. They must understand the study's research nature and agree to it in writing. It's not for those who can't handle extra imaging time, economically disadvantaged individuals, children, neonates, prisoners, or mentally disabled persons.
What is being tested?
The study is looking at how different ways of taking pictures and processing them affect the accuracy of FDG PET/CT scans used to figure out if NSCLC has spread to lymph nodes in the chest area. This is a forward-looking study that tracks participants over time.
What are the potential side effects?
Since this trial involves standard FDG PET/CT imaging procedures, side effects may include discomfort from lying still during scanning and potential reactions to contrast agents like mild allergic symptoms or temporary nausea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have NSCLC and am scheduled for a PET/CT scan.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not a child, fetus, neonate, or prisoner.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET imagingExperimental Treatment1 Intervention
PET imaging
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDG PET/CT
2014
N/A
~170

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
108,474 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
413 Previous Clinical Trials
164,601 Total Patients Enrolled
Daniel Pryma, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine
3 Previous Clinical Trials
104 Total Patients Enrolled

Media Library

FDG PET/CT Clinical Trial Eligibility Overview. Trial Name: NCT02738398 — N/A
Non-Small Cell Lung Cancer Research Study Groups: PET imaging
Non-Small Cell Lung Cancer Clinical Trial 2023: FDG PET/CT Highlights & Side Effects. Trial Name: NCT02738398 — N/A
FDG PET/CT 2023 Treatment Timeline for Medical Study. Trial Name: NCT02738398 — N/A
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top